{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:10:12Z","timestamp":1790611812855,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115832","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T22:42:20Z","timestamp":1699051340000},"page":"115832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Development, validation and clinical implementation of a UPLC-MS\/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma"],"prefix":"10.1016","volume":"238","author":[{"given":"L.A.H.","family":"Bevers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.W.J.","family":"van Ewijk \u2013 Beneken Kolmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.M.","family":"Te Brake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9635","key":"10.1016\/j.jpba.2023.115832_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"Antiretroviral Therapy Cohort C","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2023.115832_bib2","unstructured":"DHHS. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 2019 [cited 17 September 2020. Available from: \u3008https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0\u3009."},{"issue":"2","key":"10.1016\/j.jpba.2023.115832_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115832_bib4","unstructured":"Agency E.M. Assessment report Vocabria 2020 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vocabria-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2023.115832_bib5","unstructured":"Agency E.M. Assessment report Rekambys 2020 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rekambys-epar-public-assessment-report_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2023.115832_bib6","unstructured":"EACS. the European Guidelines for the treatment of HIV-positive adults in Europe: version 11.1 2022 [cited October 2022. Available from: \u3008https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09\u201310.pdf\u3009."},{"issue":"9","key":"10.1016\/j.jpba.2023.115832_bib7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.jpba.2023.115832_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.202201067","article-title":"Simultaneous quantification of (E) and (Z) isomers of rilpivirine and four degradation products in bulk and tablets by reversed-phase ultra-high-performance liquid chromatography and confirmation of all by molecular weight","volume":"46","author":"Mhaske","year":"2023","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2023.115832_bib9","unstructured":"Agency E.M. ICH guideline M10 on bioanalytical method validation and study sample analysis - Step5 2022 [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2023.115832_bib10","unstructured":"Administration USFaD. M10 Bioananalytical Method Validation And Study Sample Analysis 2022 [Guidance for Industry]. Available from: \u3008https:\/\/www.fda.gov\/media\/162903\/download\u3009."},{"issue":"5","key":"10.1016\/j.jpba.2023.115832_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1515\/cclm-2017-1104","article-title":"Practical recommendations for managing hemolyzed samples in clinical chemistry testing","volume":"56","author":"Lippi","year":"2018","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"10.1016\/j.jpba.2023.115832_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115307","article-title":"Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots","volume":"228","author":"Weld","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115832_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/jms.4506","article-title":"Development and validation of a multiplex UHPLC\u2010MS\/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine and rilpivirine in people living with HIV","author":"Courlet","year":"2020","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115832_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114698","article-title":"HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues","volume":"213","author":"Ram\u00f6ller","year":"2022","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523006015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:34:27Z","timestamp":1760002467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523006015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"alternative-id":["S0731708523006015"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115832","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development, validation and clinical implementation of a UPLC-MS\/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115832"}}